Percutaneous treatment versus hepatic resection for the treatment of small hepatocellular carcinoma

##plugins.themes.academic_pro.article.main##

Rania Hefaiedh
Mariem Sabbegh
Rym Ennaifer
Hayfa Romdhane
Houda Ben Nejma
Najet Belhadj
Lassaad Gharbi
Tahar khalfallah

Abstract

Background: Hepatocellular carcinoma is the first liver tumor worldwide. Therefore, it is a matter of debate whether surgical treatment or percutaneous treatment should be preferred for the treatment of patients with small hepatocellular carcinoma. The aim of our study was to compare the long-term outcome and the survival between surgically and percutaneously treated small hepatocellular carcinomas.

Methods: A retrospective study was performed in the department of hepatology during a period of 2009-2012. The study included all patients carrying small hepatocellular carcinoma which were divided in: group 1 including patients who underwent surgical treatment, and group 2 including patients who underwent percutaneous treatment.

Results: Among the 63 patients who were diagnosed for hepatocellular carcinoma, 28 carried a small hepatocellular carcinoma with a mean age of 63 years and sex-ratio of 0.64. Etiology of cirrhosis was viral in 96% cases. Surgical treatment (hepatic resection) was performed in 53.5% cases while percutaneous treatment was proposed for 46.5%: radiofrequency ablation in 69% and alcoholic injection in 31%. No major complications for both surgical and percutaneous treatment occurred in our study. Overall survival was significantly lower in the surgical resection group. The corresponding 6 months and 1-year overall survival rates for the surgical resection group and the percutaneous treatment group were 100%, 100%, 20%, and 52%, respectively (p=0,04). The disease free survival were not significantly different.

Conclusion: Our results showed the efficacy and safety of percutaneous ablation treatments which were better than those of surgical treatment in patients with small hepatocellular carcinoma.

Keywords:

Liver cancer - Surgery - Radiofrequency ablation - Alcoholic injection - Surv

##plugins.themes.academic_pro.article.details##

References

  1. Ben Ammar A, Cheikh I, Kchaou M, Chouaib S, Ouerghi H, Chaâbouni H. Prevalence of Helicobacter pylori infection in normal or asymptomatic patients. Tunis Med. 2003 81:200-4
  2. Correa P. The epidemiology and pathogenesis of chronic gastritis: three etiologic entites. Front Gastrointest Res 1980; 6: 98-108.
  3. Correa P. Chronic gastritis as a cancer precursor. Scand Gastroenterol 1984; 104:131-6
  4. Consensus tunisien de prévention et prise en charge du diabète de type 2. 2 ème édition 2009.
  5. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994.Am J Surg Pathol 1996; 20: 1161-81
  6. Simon L, Tornoczky J, Toth M, Jámbor M, Sudár Z. The significance of Campylobacter pylori infection in gastroenterologic and diabetic practice. Orv Hetil 1989;130:1325-9.
  7. Oldenburg B, Diepersloot RJ, Hoekstra JB. High seroprevalence of Helicobacter pylori in diabetes mellitus patients. Dig Dis Sci 1996; 41: 458-61.
  8. Perdichizzi G, Bottari M, Pallio S, Fera MT, Carbone M, Barresi G. Gastric infection by Helicobacter pylori and antral gastritis in hyperglycemic obese and in diabetic subjects. Microbiologica 1996;19:149-54
  9. Gentile S, Turco S, Oliverio B, Torella R. The role of autonomic neuropathy as a risk factor of Helicobacter pylori infection in dyspeptic patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 1998; 42:41-8.
  10. Devrajani BR, Shah SZ, Soomro AA, Devrajani T. Type 2 diabetes mellitus: A risk factor for Helicobacter pylori infection: A hospital based case-control study. Int J Diabetes Dev Ctries. 2010 ; 30: 22-6.
  11. Zelenkova J, Souckova A, Kvapil M, Soucek A, Vejvalka J, Segethova J. Helicobacter pylori and diabetes mellitus. Cas Lek Cesk. 2002; 141:575-7.
  12. Woodward M, Morrison C, McColl K. An investigation into factors associated with Helicobacter pylori infection. J Clin Epidemiol 2000; 53:175-81
  13. Xia HH, Talley NJ, Kam EP, Young LJ, Hammer J, Horowitz M. Helicobacter pylori infection is not associated with diabetes mellitus, nor with upper gastrointestinal symptoms in diabetes mellitus. Am J Gastroenterol 2001; 96: 1039-46
  14. Anastasios R, Goritsas C, Papamihail C, Trigidou R, Garzonis P, Ferti A. Helicobacter pylori infection in diabetic patients: prevalence and endoscopic findings. Eur J Intern Med 2002 ; 13:376
  15. Demir M, Gokturk HS, Ozturk NA, Kulaksizoglu M, Serin E, Yilmaz U. Helicobacter pylori prevalence in diabetes mellitus patients with dyspeptic symptoms and its relationship to glycemic control and late complications. Dig Dis Sci. 2008 ;53:2646-9
  16. Gasbarrini A , Ojetti V, Pitocco D et al. Helicobacter pylori infection in patients affected by insulin-dependent diabetes mellitus. Eur J Gastroenterol Hepatol 1998;10:469-472
  17. De Luis D.A., De la Calle H., Roy G. et al. Helicobacter pylori infection and insulin-dependent diabetes mellitus. Diab Res Clin Pract 1998; 39:143-6
  18. Marrollo M, Latella G, Melideo D, et al. Increased prevalence of Helicobacter pylori in patients with diabetes mellitus. Dig Liver Dis. 2001; 33:21-9
  19. Antwi Ch, Krahulec B, Michalko L, Strbova L, Hlinstakova S, Balazovjech I. Does diabetic autonomic neuropathy influence the clinical manifestations of reflux esophagitis? Bratisl Lek Listy. 2003; 104: 139-42.
  20. Mittal RK, Holloway RH, Penagini R, Blackshaw LA, Dent J. Transient lower esophageal sphincter relaxation. Gastroenterology. 1995; 109:601-10.
  21. Holloway RH, Hongo M, Berger K, McCallum RW. Gastric distention: a mechanism for postprandial gastroesophageal reflux. Gastroenterology. 1985; 89: 779-784.